ArticleVirology journal2021
Resource-efficient internally controlled in-house real-time PCR detection of SARS-CoV-2.
Article in Virology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.Scientific reports · 2023Trial
- vPro-MS enables identification of human-pathogenic viruses from patient samples by untargeted proteomics.Nature communications · 2025Article
- Aging and Viral Evolution Impair Immunity Against Dominant Pan-Coronavirus-Reactive T Cell Epitope.European journal of immunology · 2025Article
- Electron microscopy images and morphometric data of SARS-CoV-2 variants in ultrathin plastic sections.Scientific data · 2024Article
- Dermorphin [D-Arg2, Lys4] (1-4) Amide Alleviates Frostbite-Induced Pain by Regulating TRP Channel-Mediated Microglial Activation and Neuroinflammation.Molecular neurobiology · 2024Article
- Article
- The Diagnostic Performance of Various Clinical Specimens for the Detection of COVID-19: A Meta-Analysis of RT-PCR Studies.Diagnostics (Basel, Switzerland) · 2023Review
- SARS-CoV-2 seroconversion in children attending daycare versus adults in Germany between October 2020 and June 2021.Communications medicine · 2023Article
- Article
- Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study.Infection · 2023Article
- Flexible upscaling of laboratory PCR testing capacity at the Robert Koch Institute during the SARS-CoV-2 pandemic.Virology journal · 2023Article
- Performance of 20 rapid antigen detection tests to detect SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants using a clinical specimen panel from January 2022, Berlin, Germany.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- Single-Center Experience in Detecting Influenza Virus, RSV and SARS-CoV-2 at the Emergency Department.Viruses · 2023Article
- Visualization of SARS-CoV-2 particles in naso/oropharyngeal swabs by thin section electron microscopy.Virology journal · 2023Article
- Article
- Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity.Frontiers in immunology · 2023Article
- Comparative Analysis ofDiagnostics (Basel, Switzerland) · 2022Article
- Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020.Scientific reports · 2022Article
- Canine real-time detection of SARS-CoV-2 infections in the context of a mass screening event.BMJ global health · 2022Article
- Evaluation of 11 commercially available PCR kits for the detection of monkeypox virus DNA, Berlin, July to September 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe reliable detection of SARS-CoV-2 has become one of the most important contributions to COVID-19 crisis management. With the publication of the first sequences of SARS-CoV-2, several diagnostic PCR assays have been developed and published. In addition to in-house assays the market was flooded with numerous commercially available ready-to-use PCR kits, with both approaches showing alarming shortages in reagent supply.
aimHere we present a resource-efficient in-house protocol for the PCR detection of SARS-CoV-2 RNA in patient specimens (RKI/ZBS1 SARS-CoV-2 protocol).
methodsTwo duplex one-step real-time RT-PCR assays are run simultaneously and provide information on two different SARS-CoV-2 genomic regions. Each one is duplexed with a control that either indicates potential PCR inhibition or proves the successful extraction of nucleic acid from the clinical specimen.
resultsLimit of RNA detection for both SARS-CoV-2 assays is below 10 genomes per reaction. The protocol enables testing specimens in duplicate across the two different SARS-CoV-2 PCR assays, saving reagents by increasing testing capacity. The protocol can be run on various PCR cyclers with several PCR master mix kits.
conclusionThe presented RKI/ZBS1 SARS-CoV-2 protocol represents a cost-effective alternative in times of shortages when commercially available ready-to-use kits may not be available or affordable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.